홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

Dimethylformamide → N2-(1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)-N-3-dodecylpyrazine-2,3-dicarboxamide

HRID 241533
인쇄

반응식

HRID 241533 반응식
[CH:1]1[C:7](N)=[N:6][C:4](=[O:5])[N:3]([C@@H:9]2[O:13][C@H:12]([CH2:14][OH:15])[C@@H:11]([OH:16])[C:10]2([F:18])[F:17])[CH:2]=1.Cl.[CH2:20]([NH:32][C:33]([C:35]1[C:36]([C:41]([OH:43])=O)=[N:37][CH:38]=[CH:39][N:40]=1)=[O:34])[CH2:21][CH2:22][CH2:23][CH2:24][CH2:25][CH2:26][CH2:27][CH2:28][CH2:29]CC.F[P-](F)(F)(F)(F)F.N1(O[P+](N2CCCC2)(N2CCCC2)N2CCCC2)[C:55]2C=CC=C[C:54]=2N=N1.C[N:78](C)C=O>CN(C)C1C=CN=CC=1>[F:17][C:10]1([F:18])[C@H:11]([OH:16])[C@@H:12]([CH2:14][OH:15])[O:13][C@H:9]1[N:3]1[CH:2]=[CH:1][C:7]([N:32]([CH:20]([CH2:21][CH2:22][CH2:23][CH2:24][CH2:25][CH2:26][CH2:27][CH2:28][CH3:29])[CH2:54][CH3:55])[C:33]([C:35]2[C:36]([C:41]([NH2:78])=[O:43])=[N:37][CH:38]=[CH:39][N:40]=2)=[O:34])=[N:6][C:4]1=[O:5]
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

6

반응물 4

HCID 6228DimethylformamideHCID 60749Gemcitabine HydrochlorideHCID 2724699PyBOPHCID 667716903-(Dodecylcarbamoyl)pyrazine-2-carboxylic acid2회

생성물 1

HCID 66977836N2-(1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)-N-3-dodecylpyrazine-2,3-dicarboxamide

시약·촉매·용매 1

HCID 142844-(Dimethylamino)pyridine촉매

실험 절차

Gemcitabine hydrochloride (200 mg, 0.67 mmol), 3-(dodecylcarbamoyl)pyrazine-2-carboxylic acid (325 mg, 1.01 mmol), benzotriazole-1-yl-oxytripyrrolidinylphosphonium hexafluorophosphate (327.6 mg, 0.74 mmol), and 4-dimethylaminopyridine (98 mg, 0.80 mmol) were dissolved in N,N-Dimethylformamide (10 mL) and stirred at room temperature overnight. The reaction mixture was poured into the water, then extracted three times with ethyl acetate. The isolated organic phase was dried with anhydrous Na2SO4. The solvent was removed by vaporizing under reduced pressure. The residue was purified by silica column chromatography (developing agent: dichloromethane/methanol=10/1) to produce 290 mg of N2-(1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)-N-3-dodecylpyrazine-2,3-dicarboxamide (compound No. 37). LC purity 98% (UV 254). LC-MS m/z 581 [M+H]+, (molecular formula: C27H38F2N6O6, molecular weight: 580). The structure and characterization data of the compound were shown in Table 1.

후처리

  1. extractionextracted three times with ethyl acetate
  2. dry with materialThe isolated organic phase was dried with anhydrous Na2SO4
  3. customThe solvent was removed
  4. customThe residue was purified by silica column chromatography (developing agent: dichloromethane/methanol=10/1)

출처 및 근거

ORD 기록
ord-72b95fdc84c042fba070fcfcc5d49b7a
출처 데이터셋
uspto-grants-2014_02
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US08653048B2

반응 노트

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트